This study is looking at how well vaccines work in people with certain blood cancers, specifically chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, and some non-Hodgkin lymphomas. Researchers want to see how your body responds to vaccines like AREXVY, ABRYSVO (for RSV), PREVNAR 20, PNEUMOVAX 23, PREVNAR 13 (for pneumonia), and Heplisav-B (for Hepatitis B). People with these cancers often have a weaker immune response, and some cancer treatments like Bruton tyrosine kinase inhibitors (BTKis) might also affect vaccine effectiveness. The main goal is to measure your immune response (serologic response) to each vaccine about four weeks after you've completed the vaccine series. This study is currently unclear about its recruitment status and plans to enroll about 350 participants aged 18 to 90.

Study design

This interventional study plans to enroll about 350 participants. It is not specified if it is randomized or blinded.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your immune response will be measured at 4 weeks after completing the vaccine series.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.